Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesis. We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6). Here we show, through a combination of mapping critical recombinants, identifying individuals with germline mutations and screening known and predicted transcripts, that this gene encodes fumarate hydratase, an enzyme of the tricarboxylic acid cycle. Leiomyomatosis-associated mutations are predicted to result in absent or truncated protein, or substitutions or deletions of highly conserved amino acids. Activity of fumarate hydratase is reduced in lymphoblastoid cells from individuals with leiomyomatosis. This enzyme acts as a tumor suppressor in familial leiomyomata, and its measured activity is very low or absent in tumors from individuals with leiomyomatosis. Mutations in FH also occur in the recessive condition fumarate hydratase deficiency, and some parents of people with this condition are susceptible to leiomyomata. Thus, heterozygous and homozygous or compound heterozygous mutants have very different clinical phenotypes. Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“germline mutations in FH cause hereditary leiomyomatosis and renal cell cancer (HLRCC) (7).”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [7]
In the citing paper
“Familial cancer syndromes caused by fumarate hydratase (FH) or succinate dehydrogenase (SDH) deletion suggest that these TCA enzymes can behave as classical tumor suppressors.”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Tomlinson et al., 2002
In the citing paper
“Similarly, germline mutations in the broadly expressed enzyme fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell carcinoma, a familial syndrome of uterine and cutaneous leiomyomas and kidney cancer, without susceptibility to more common tumors (11).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [11]
In the citing paper
“In 2001, mutation of fumarate hydratase leading to its inactivation was discovered in renal cell cancer129. Mutation of this enzyme leads to fumarate accumulation not only in skin cancer and uterine leiomyomas but also in breast, bladder, and Leydig cell tumors130.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [130]
In the citing paper
“Consistently, heterozygous germline mutations in genes encoding the TCA cycle enzymes involved in the breakdown of these metabolites—SDH and FH—have been shown to facilitate the pathogenesis of certain rare cancers (e.g., paragangliomas) and inherited cancer-predisposition syndromes (181, 182, 183).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [183]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultAstuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875
Inherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669
Fumarase C, the stable fumarase of Escherichia coli, is controlled by the soxRS regulon.
Liochev, S. I., & Fridovich, I. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5892 · Cited by 239
The VHL tumour-suppressor gene paradigm
Kaelin, W. G., & Maher, E. R. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01558-3 · Cited by 213 · cited 1×
“, individuals with von Hippel–Lindau syndrome are predisposed to both phaeochromocytomas and renal carcinoma”
BackgroundKiuru, M., Launonen, V., Hietala, M., Aittomäki, K., Vierimaa, O., Salovaara, R., Arola, J., Pukkala, E., Sistonen, P., Herva, R., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61757-9 · Cited by 209
Bourgeron, T., Chretien, D., Poggi-Bach, J., Doonan, S., Rabier, D., Letouzé, P., Munnich, A., Rötig, A., Landrieu, P., & Rustin, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117261 · Cited by 160
Alam, N. A., Bevan, S., Churchman, M., Barclay, E., Barker, K., Jaeger, E. E. M., Nelson, H. M., Healy, E., Pembroke, A. C., Friedmann, P. S., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/320124 · Cited by 160
Familial predisposition to uterine leiomyomas
Vikhliaeva, E. M., Сагдуллаевна, Х. З., & Nd, F. (1995) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(95)02533-i · Cited by 152 · cited 1×
“gif" NDATA ITEM> ]> Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesi”
Background
Cited by
Items 401–500 of 1,000
The Genetics of Uterine Leiomyomata
Stewart, E. A., & Morton, C. C. (2006) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000206161.84965.0b · Cited by 72
Imaging of tumor glucose utilization with positron emission tomography
Bürkle, A., & Weber, W. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9151-x · Cited by 79
“Inherited or somatic mutations in SDHB, SDHC and SDHD have been shown to lead to the development of pheochromocytoma, whereas inherited mutations in FH can cause leiomyoma, leiomyosarcoma or renal-cell carcinoma [67–70].”
BackgroundAshrafian, H., O'Flaherty, L., Adam, J., Steeples, V., Chung, Y.-L., East, P., Vanharanta, S., Lehtonen, H., Nye, E., Hatipoglu, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1949 · Cited by 72
Cleven, A. H. G., Suijker, J., Agrogiannis, G., Bruijn, I. H. B., Frizzell, N., Hoekstra, A. S., Wijers‐Koster, P. M., Cleton-Jansen, A., & Bovée, J. V. M. G. (2017) · Clinical Sarcoma Research · doi:10.1186/s13569-017-0074-6 · Cited by 73
“Other TCA cycle enzymes involved in cancer are succinate dehydrogenase (SDH) in hereditary paragangliomas [28–31] and gastrointestinal stromal tumour (GIST) [32], and fumarate hydratase (FH) in hereditary leiomyomas and renal cell cancer (HLRCC) [33].”
BackgroundGermline Fumarate Hydratase Mutations in Families with Multiple Cutaneous and Uterine Leiomyomata
Martı́nez-Mir, A., Gläser, B., Chuang, G. S., Horev, L., Waldman, A., Engler, D. E., Gordon, D., Spelman, L. J., Hatzibougias, I., Green, J., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12499.x · Cited by 72
“Seventeen of 42 families reported by Tomlinson et al (2002) did not display mutations in the FH gene.”
BackgroundMethodInfluentialBarker, K. T., Bevan, S., Wang, R., Lu, Y.-J., Flanagan, A. M., Bridge, J. A., Fisher, C., Finlayson, C. J., Shipley, J., & Houlston, R. S. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600502 · Cited by 72
Energy depletion in seizures: Anaplerosis as a strategy for future therapies
Kovac, S., Abramov, A. Y., & Walker, M. C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.012 · Cited by 74
Cancer-associated genodermatoses: Skin neoplasms as clues to hereditary tumor syndromes
Ponti, G., Pellacani, G., Seidenari, S., Pollio, A., Muscatello, U., & Tomasi, A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.07.001 · Cited by 71
Targeting the Met signaling pathway in renal cancer
Giubellino, A., Linehan, W. M., & Bottaro, D. P. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.43 · Cited by 71
Morris, M. R., Maina, E., Morgan, N. V., Gentle, D., Astuti, D., Moch, H., Kishida, T., Yao, M., Schraml, P., Richards, F. M., et al. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.011767 · Cited by 70
Enzymatic features of the glucose metabolism in tumor cells
Herling, A., König, M., Bulik, S., & Holzhütter, H. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08174.x · Cited by 74
HIF and fumarate hydratase in renal cancer
Sudarshan, S., Linehan, W. M., & Neckers, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603547 · Cited by 71
“…Bethesda, MD 20892-1107, USA; E-mail: len@helix.nih.gov British Journal of Cancer (2007) 96, 403 – 407 & 2007 Cancer Research UK All rights reserved 0007 – 0920/07 $30.00 www.bjcancer.com appears that FH acts as a tumour suppressor gene and fits Knudson’s two-hit model (Tomlinson et al, 2002).”
BackgroundInfluentialCutaneous Manifestations of Internal Malignancy
Ehst, B. D., Minzer-Conzetti, K., Swerdlin, A., & Devere, T. S. (2010) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2010.01.003 · Cited by 69
Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry
Juhlin, C. C. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09675-0 · Cited by 69
Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma
Mariño‐Enríquez, A., & Bovée, J. V. M. G. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.009 · Cited by 73
Precision medicine from the renal cancer genome
Riazalhosseini, Y., & Lathrop, M. G. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.133 · Cited by 80
Siegler, L., Erber, R., Burghaus, S., Brodkorb, T., Wachter, D. L., Wilkinson, N., Bolton, J., Stringfellow, H. F., Haller, F., Beckmann, M. W., et al. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2292-6 · Cited by 69
Røsland, G. V., Dyrstad, S. E., Tusubira, D., Helwa, R., Tan, T. Z., Lotsberg, M. L., Pettersen, I. K. N., Berg, A., Kindt, C. K., Hoel, F., et al. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0197-8 · Cited by 72
Familial risks of cancer as a guide to gene identification and mode of inheritance
Hemminki, K., & Li, X. (2004) · International Journal of Cancer · doi:10.1002/ijc.20107 · Cited by 69
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68
The prospect of precision therapy for renal cell carcinoma
Ciccarese, C., Brunelli, M., Montironi, R., Fiorentino, M., Iacovelli, R., Heng, D. Y. C., Tortora, G., & Massari, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.003 · Cited by 71
Whitworth, J., Smith, P., Martín, J., West, H. D., Luchetti, A., Rodger, F., Clark, G. R., Carss, K., Stephens, J. C., Stirrups, K. E., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.04.013 · Cited by 77
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy
Pfaffenroth, E. C., & Linehan, W. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.779 · Cited by 80
“Functional inactivation of the remaining second copy has been found in most HLRCC papillary type-2 renal tumors, cutaneous leiomyomas, and uterine leiomyomas [78-80] .”
BackgroundGross, K. L., Panhuysen, C. I. M., Kleinman, M. S., Goldhammer, H., Jones, E. S., Nassery, N., Stewart, E. A., & Morton, C. C. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20079 · Cited by 67
Yang, Y., Valera, V., Sourbier, C., Vocke, C. D., Wei, M., Pike, L., Huang, Y., Merino, M. A., Bratslavsky, G., Wu, M., et al. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.05.001 · Cited by 65
“A high mutation detection rate in HLRCC families [4;5;29] enables the early detection of atrisk individuals and allows for the early initiation of therapy while the tumor is still small.”
BackgroundShioi, K., Komiya, A., Hattori, K., Huang, Y. K., Sano, F., Murakami, T., Nakaigawa, N., Kishida, T., Kubota, Y., Nagashima, Y., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1737 · Cited by 67
Qin, Y., Deng, Y., Ricketts, C. J., Srikantan, S., Wang, E., Maher, E. R., & Dahia, P. L. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt638 · Cited by 70
Cellular oxygen sensing in health and disease
Mole, D. R., & Ratcliffe, P. J. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0632-x · Cited by 79
“Similarly, germline mutation in fumarate hydratase (FH) has been linked to cutaneous and uterine leiomyomata and renal cell cancer [79, 95, 98 , 99].”
Studying Cancer Families to Identify Kidney Cancer Genes
Zbar, B., Klausner, R. D., & Linehan, W. M. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152514 · Cited by 78
Hypoxia and Hypoxia Inducible Factors (HIF) as Important Regulators of Tumor Physiology
Acker, T., & Plate, K. H. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_14 · Cited by 75
Xu, Y., Kong, W., Cao, M., Wang, J., Wang, Z., Zheng, L., Wu, X. O., Cheng, R., He, W., Yang, B., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.05.029 · Cited by 67
Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer
Zecchini, V. R., Madhu, B., Russell, R. R., Pértega‐Gomes, N., Warren, A. Y., Gaude, E., Borlido, J., Stark, R., Zecchini, H. I., Rao, R. B., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201386874 · Cited by 66
“Somatic mutations in SDH and loss-of-function germline mutations in FH have been associated with many cancers (Tomlinson et al, 2002; Lehtonen et al, 2006; Korpershoek et al, 2011).”
BackgroundInsights into the Pathogenesis and Treatment of Cancer from Inborn Errors of Metabolism
Erez, A., Shchelochkov, O. A., Plon, S. E., Scaglia, F., & Lee, B. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.03.005 · Cited by 67
Rinaldi, G., Rossi, M., & Fendt, S. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1397 · Cited by 63
“Similarly, loss of fumarate hydratase (FH) expression, with consequent fumarate accumulation, is found in the familial cancer syndrome HLRCC (hereditary leiomyomatosis and renal cell cancer), as well as in paraganglioma and pheochromocytoma.(131) Gain-of-function mutations of isocitrate dehydrogenase 1 (IDH1) and isoc…”
BackgroundDual mode action of mangiferin in mouse liver under high fat diet
Lim, J., Liu, Z., Apontes, P., Feng, D., Pessin, J. E., Sauve, A. A., Angeletti, R. H., & Chi, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090137 · Cited by 64
HIF, a missing link between metabolism and cancer
Esteban, M. A., & Maxwell, P. H. (2005) · Nature Medicine · doi:10.1038/nm1005-1047 · Cited by 69
Sudarshan, S., Pinto, P. A., Neckers, L., & Linehan, W. M. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0711 · Cited by 65
“Analysis of families with this disorder has identified the responsible gene locus as FH”
BackgroundIs Glioblastoma an Epigenetic Malignancy?
Maleszewska, M., & Kaminska, B. (2013) · Cancers · doi:10.3390/cancers5031120 · Cited by 57
Metabolic synthetic lethality in cancer therapy
Zecchini, V. R., & Frezza, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.12.003 · Cited by 66
Choi, Y., Keam, B., Kim, M., Yoon, S., Kim, D., Choi, J. G., Seo, J. Y., Park, I., & Lee, J. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.086 · Cited by 63
Uterine Fibroids: Hiding in Plain Sight
Stewart, E. A., & Nowak, R. A. (2021) · Physiology · doi:10.1152/physiol.00013.2021 · Cited by 70
Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy
Chen, C., Wang, Z., & Qin, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935536 · Cited by 75
“respectively contributes to the stacking up of succinate and fumarate (Baysal et al., 2000; Tomlinson et al., 2002; Gottlieb and Tomlinson, 2005), both of which interfere with α KGdependent dioxygenases, namely DNA and histone demethylase (Nowicki and Gottlieb, 2015).”
BackgroundShanmugasundaram, K., Nayak, B., Shim, E., Livi, C. B., Block, K. L., & Sudarshan, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568162 · Cited by 66
Comati, A., Beck, H., HALLIDAY, W. C., Snipes, G. J., Plate, K. H., & Acker, T. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31802d9011 · Cited by 62
“Heterozygous mutations affecting succinate dehydrogenase and fumarate hydratase are associated with hereditary predispositions to various highly vascularized tumors (49, 50).”
Mitochondrial Dysfunction Impairs Tumor Suppressor p53 Expression/Function
Compton, S. L., Kim, C. G., Griner, N. B., Potluri, P., Scheffler, I. E., Sen, S., Jerry, D. J., Schneider, S. S., & Yadava, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.163063 · Cited by 65
Nitric oxide and tumor metabolic reprogramming
Lopez-Sanchez, L. M., Aranda, E., & Rodríguez‐Ariza, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113769 · Cited by 67
Tumor and metastasis suppression by the human RNASET2 gene
Acquati, F., Possati, L., Ferrante, L., Campomenosi, P., Talevi, S., Bardelli, S., Margiotta, C., Russo, A., Bortoletto, E., Rocchetti, R., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.5.1159 · Cited by 62
Bulun, S. E., Yin, P., Wei, J., Zuberi, A., Iizuka, T., Suzuki, T., Saini, P., Goad, J., Parker, J. B., Adli, M., et al. (2025) · Physiological Reviews · doi:10.1152/physrev.00010.2024 · Cited by 71
Malinoc, A., Sullivan, M., Wiech, T., Schmid, K. W., Jilg, C. A., Straeter, J., Değer, S., Hoffmann, M. M., Bosse, A., Rasp, G., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0324 · Cited by 62
“Germline FH mutations are associated with hereditary type 2 pRCC (Tomlinson et al. 2002).”
BackgroundChemically induced pheochromocytomas in rats: mechanisms and relevance for human risk assessment
Greim, H. A., Hartwig, A., Reuter, U., Richter-Reichhelm, H.-B., & Thielmann, H. W. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440903190861 · Cited by 63
Glutarate regulates T cell metabolism and anti-tumour immunity
Minogue, E., Cunha, P. P., Wadsworth, B. J., Grice, G. L., Sah‐Teli, S. K., Hughes, R., Bargiela, D., Quaranta, A., Zurita, J., Antrobus, R., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00855-2 · Cited by 67
Peng, X., Gong, F., Zhao, Y., Zhou, L., Xie, Y., Liao, H.-L., Lin, H., Li, Z., Tang, M., & Tong, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027309 · Cited by 68
“It had been reported that individuals with loss of FH activity are at risk for the development of leiomyomas of the skin and uterus (fibroids) as well as kidney cancer [28,29,30].”
BackgroundHidden features: exploring the non-canonical functions of metabolic enzymes
Huangyang, P., & Simon, M. C. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033365 · Cited by 61
Máximo, V., Lima, J. P., Soares, P., & Sobrinho-Simões, M. A. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0766-2 · Cited by 73
“[46] reported that heterozygous FH mutations predispose to dominantly inherited uterine fibroids, skin leiomyomata and type II papillary renal cell cancer, the so-called hereditary leiomyomas and renal cell carcinoma (HLRCC) syndrome.”
BackgroundChuang, G. S., Martı́nez-Mir, A., Geyer, A. S., Engler, D. E., Gläser, B., Cserhalmi‐Friedman, P. B., Gordon, D., Horev, L., Lukash, B., Herman, E., et al. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.08.051 · Cited by 60
“Interestingly, MCL has been reported in the carrier mother of one infant with FHD.(7) However, a recent”
BackgroundInfluentialVahidnezhad, H., Youssefian, L., & Uitto, J. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.331 · Cited by 65
Precision medicine in pheochromocytoma and paraganglioma: current and future concepts
Björklund, P., Pacák, K., & Crona, J. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12507 · Cited by 67
Heterozygosity for a Mendelian disorder as a risk factor for complex disease
Sidransky, E. (2006) · Clinical Genetics · doi:10.1111/j.1399-0004.2006.00688.x · Cited by 59
“Another example is the finding that fumarate hydratase, a protein involved in the Krebs cycle, is a tumor suppressor gene (20).”
BackgroundMolecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets
Iliopoulos, O. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8948 · Cited by 67
Colorectal cancer and inherited mutations in base-excision repair
Chow, E. C., Thirlwell, C., Macrae, F., & Lipton, L. R. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01595-5 · Cited by 59
Basic Research in Kidney Cancer
Oosterwijk, E., Rathmell, W. K., Junker, K., Brannon, A. R., Pouliot, F., Finley, D. S., Mulders, P., Kırkalı, Z., Uemura, H., & Belldegrun, A. S. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.048 · Cited by 66
“A more rare, but also highly aggressive type of papillary type II renal cell carcinoma has been associated with mutations in the fumarate hydratase gene [23], although the relevance of this mutation in sporadic disease is unknown.”
Si, R.-W., Zhai, D.-D., Liao, Z.-H., Gao, L., & Yong, Y. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.12.035 · Cited by 58
5-Hydroxymethylcytosine Profiling as an Indicator of Cellular State
Laird, A., Thomson, J. P., Harrison, D. J., & Meehan, R. R. (2013) · Epigenomics · doi:10.2217/epi.13.69 · Cited by 62
TERT promoter mutations in clear cell renal cell carcinoma
Hosen, M. I., Rachakonda, P. S., Heidenreich, B., Sitaram, R. T., Ljungberg, B., Roos, G., Hemminki, K., & Kumar, R. (2014) · International Journal of Cancer · doi:10.1002/ijc.29279 · Cited by 59
Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer
Ni, R., Li, Z.-W., Li, L., Peng, D., Yue, M., Li, L., & Liu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1143798 · Cited by 54
“Mutations occur throughout the FH gene, and heterozygous mutations in this gene are related to dominantly inherited uterine fibroids, hereditary leiomyomatosis, and renal cell carcinoma (81, 82).”
BackgroundFH Variant Pathogenicity Promotes Purine Salvage Pathway Dependence in Kidney Cancer
Wilde, B. R., Chakraborty, N., Matulionis, N., Hernandez, S., Ueno, D., Gee, M. E., Esplin, E. D., Ouyang, K., Nykamp, K., Shuch, B. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0874 · Cited by 59
The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy
Wu, J., Liu, N., Chen, J., Tao, Q., Li, Q., Li, J., Chen, X., & Peng, C. (2024) · Research · doi:10.34133/research.0351 · Cited by 71
“Heterozygous germline mutations in FH predispose patients to hereditary leiomyomatosis and renal cell cancer (HLRCC), which is a cancer syndrome characterized by uterine fibroids, skin leiomyomata, and aggressive papillary renal cell cancer [147].”
BackgroundAlrashdi, I., Levine, S., Paterson, J., Saxena, R., Patel, S. R., Depani, S., Hargrave, D. R., Pritchard‐Jones, K., & Hodgson, S. V. (2009) · Familial Cancer · doi:10.1007/s10689-009-9306-0 · Cited by 57
“Mutations in FH predispose to the dominantly inherited cancer syndrome of predisposition to uterine fibroids, skin leiomyoma, and renal cell cancer [3].”
BackgroundEpigenetic regulation in RCC: opportunities for therapeutic intervention?
Larkin, J., Goh, X. Y., Vetter, M. H. F., Pickering, L. M., & Swanton, C. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2011.236 · Cited by 61
“HLRCC syndrome is caused by a defect in the gene encoding the Krebs cycle enzyme fumarate hydratase located at 1q42 and is characterized by cutaneous and uterine leiomyomas in addition to renal tumors”
BackgroundLocke, M., Ghazaly, E. A., Freitas, M. O., Mitsinga, M., Lattanzio, L., Nigro, C. L., Nagano, A., Wang, J., Chelala, C., Szlosarek, P. W., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.097 · Cited by 62
“…of tumor cells and have identified numerous mutations in metabolic enzymes, including isocitrate dehydrogenase 1, fumarate hydratase, and succinate dehydrogenase, in a range of tumor types (Frezza et al., 2011b; King et al., 2006; Muller et al., 2012; Tomlinson et al., 2002; Yan et al., 2009).”
BackgroundKerins, M. J., Vashisht, A. A., Liang, B. X.-T., Duckworth, S. J., Praslicka, B. J., Wohlschlegel, J. A., & Ooi, A. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-17 · Cited by 56
Fumarase: From the TCA Cycle to DNA Damage Response and Tumor Suppression
Leshets, M., Silas, Y., Lehming, N., & Pines, O. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00068 · Cited by 58
Skala, S. L., Dhanasekaran, S. M., & Mehra, R. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0216-ra · Cited by 58
Metabolic regulation in the immune response to cancer
Wu, Q., Yu, X., Li, J., Sun, S., & Tu, Y. (2021) · 癌症:英文版 · doi:10.1002/cac2.12182 · Cited by 62
“Published evidence showed that the glutaminase inhibitor bis-2-(5-phenylacetamido-1,2,4-thiadiazol2-yl)ethyl sulfide (BPTES) significantly reduced the concentrations of fumarate in the immune response induced by β-glucan [63].”
BackgroundInterplay between Mitochondrial Metabolism and Cellular Redox State Dictates Cancer Cell Survival
Foo, B. J.-A., Eu, J. Q., Hirpara, J. L., & Pervaiz, S. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/1341604 · Cited by 58
Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer
Lanzetti, L. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01402-6 · Cited by 65
The clinical implications of the genetics of renal cell carcinoma
Rosner, I. L., Bratslavsky, G., Pinto, P. A., & Linehan, W. M. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.11.001 · Cited by 56
“(42) Fumarate hydratase is an essential enzyme for the conversion of fumarate to malate in the Krebs cycle.”
From Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma
Lussey‐Lepoutre, C., Thibault, C., Buffet, A., Morin, A., Badoual, C., Bénit, P., Rustin, P., Ottolenghi, C., Janin, M., Castro‐Vega, L. J., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.027 · Cited by 58
Pithukpakorn, M., Wei, M.-H., Toure, O., Steinbach, P. J., Glenn, G. M., Zbar, B., Linehan, W. M., & Toro, J. R. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.041087 · Cited by 56
Wentzel, J. F., Lewies, A., Bronkhorst, A. J., van Dyk, E., Plessis, D., & Pretorius, P. J. (2017) · Biochimie · doi:10.1016/j.biochi.2017.01.004 · Cited by 59
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase
Ilic, N., Birsoy, K., Aguirre, A. J., Kory, N., Pacold, M. E., Singh, S., Moody, S. E., DeAngelo, J. D., Spardy, N. A., Freinkman, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617922114 · Cited by 51
Smooth Muscle Tumors of the Female Genital Tract
Devereaux, K. A., & Schoolmeester, J. K. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.02.004 · Cited by 55
Koopman, K., Gaal, J., & de Krijger, R. R. (2019) · Cancers · doi:10.3390/cancers11081070 · Cited by 57
Familial clustering of Leiomyomatosis peritonealis disseminata: an unknown genetic syndrome?
Halama, N., Grauling-Halama, S., & Daboul, I. (2005) · BMC Gastroenterology · doi:10.1186/1471-230x-5-33 · Cited by 55
“Mutations in the fumarase hydratase (FH) gene, an enzyme which is involved in the mitochondrial tri-carboxylic acid cycle, are known to cause leiomyomas [ 20 ,21].”
BackgroundGaster, M., Nehlin, J. O., & Minet, A. D. (2012) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.656653 · Cited by 60
Alrefae, M., Wong, N., Patenaude, F., Bégin, L. R., & Foulkes, W. D. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0773 · Cited by 55
“The gene underlying hereditary leiomyomatosis and renal cell carcinoma (HLRCC) was located on chromosome 1 by linkage analysis, and subsequently identified in 2002”
BackgroundEpigenomic and enhancer dysregulation in uterine leiomyomas
Mlodawska, O. W., Saini, P., Parker, J. B., Wei, J., Bulun, S. E., Simon, M. A., & Chakravarti, D. (2022) · Human Reproduction Update · doi:10.1093/humupd/dmac008 · Cited by 60
Epigenetics of Kidney Cancer And Bladder Cancer
Hoffman, A. M., & Cairns, P. (2011) · Epigenomics · doi:10.2217/epi.10.64 · Cited by 54
Lessons from the skin—cutaneous features of familial cancer
Winship, I., & Dudding, T. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70126-8 · Cited by 62
The role of mitochondria in the oncogenic signal transduction
Frezza, C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.12.013 · Cited by 57
Sudarshan, S., Shanmugasundaram, K., Naylor, S. L., Lin, S., Livi, C. B., O'Neill, C. F., Parekh, D. J., Yeh, I.-T., Sun, L.-Z., & Block, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021037 · Cited by 52
“Germline mutations of FH, the gene that encodes for the tricarboxylic acid TCA (TCA) cycle enzyme fumarate hydratase, are associated with an inherited form of cancer referred to as Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC).”
BackgroundInfluentialProtein lysine acetylation guards metabolic homeostasis to fight against cancer
Xu, W., Li, Y., LIU, C., & Zhao, S. (2013) · Oncogene · doi:10.1038/onc.2013.163 · Cited by 58
Canevari, R. D. A., Pontes, A., Rosa, F. E., Rainho, C. A., & Rogatto, S. R. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.02.097 · Cited by 53
“It was shown that germline mutations of fumarate hydratase (FH gene) are responsible for the inherited syndromes of multiple cutaneous and uterine leiomyomas (MCUL, OMIM 150800) and of hereditary leiomyomatosis and renal cell cancer (HLRCC, OMIM 605839).(24) These syndromes are inherited as autosomal dominant disorder…”
BackgroundFurge, K. A., Tan, M.-H., Dykema, K. J., Kort, E. J., Stadler, W. M., Yao, X., Zhou, M., & Teh, B. T. (2007) · Oncogene · doi:10.1038/sj.onc.1210256 · Cited by 53
“For example, loss of function mutations in the FH gene have been associated with the development of hereditary papillary RCC (Tomlinson et al., 2002).”
BackgroundZeviani, M., & Carelli, V. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200310000-00004 · Cited by 53
Post-translational modifications of Keap1: the state of the art
Song, Y., Qu, Y., Mao, C., Zhang, R., Jiang, D., & Sun, X. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1332049 · Cited by 65
Identification and characterization of Birt–Hogg–Dubé associated renal carcinoma
Murakami, T., Sano, F., Huang, Y. K., Komiya, A., Baba, M., Osada, Y., Nagashima, Y., Kondo, K., Nakaigawa, N., Miura, T., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2139 · Cited by 52
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC
Yamasaki, T., Tran, T. A. T., Öz, O. K., Raj, G. V., Schwarz, R. E., DeBerardinis, R. J., Zhang, X., & Brugarolas, J. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2010.234 · Cited by 58
“HLRCC is a syndrome with an autosomal dominant pattern of inheritance caused by germline loss-of-function mutations in the gene encoding fumarate hydratase (FH)”
Yang, C., Harrison, C., Jin, E. S., Chuang, D. T., Sherry, A. D., Malloy, C. R., Merritt, M. E., & DeBerardinis, R. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.543637 · Cited by 51
Evolving therapeutic targets in renal cell carcinoma
Singer, E. A., Gupta, G. N., Marchalik, D., & Srinivasan, R. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835fc857 · Cited by 52
“Patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), which is associated with type II pRCC, offer insights into the genetic and molecular alterations underlying this aggressive cancer [4,32,33].”
Background
Metadata
- Authors
- The Multiple Leiomyoma Consortium
- Venue
- Nature Genetics
- Published
- 2002-02-25
- Volume
- 30
- Issue
- 4
- Pages
- 406-410
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1967291345
- Cited by
- 1,635
- References
- 17
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 64 · 2023: 57 · 2022: 65 · 2021: 80 · 2020: 93 · 2019: 86 · 2018: 81 · 2017: 90 · 2016: 106 · 2015: 89 · 2014: 85 · 2013: 82 · 2012: 82
- FWCI
- 56.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- U.S. Public Health Service (U59309)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- fumarate hydratase, FH gene, germline mutations, uterine fibroids, cutaneous leiomyoma, papillary renal cell carcinoma, cancer susceptibility, tumor suppressor, fumarate hydratase deficiency, compound heterozygosity, TCA cycle, fibroid pathogenesis
- MeSH terms
- Alleles, Carcinoma, Papillary, Carcinoma, Renal Cell, Chromosomes, Human, Pair 1, Exons, Female, Fumarate Hydratase, Genes, Dominant, Genetic Markers, Humans, Kidney Neoplasms, Leiomyoma, Male, Mutation, Pedigree, Recombination, Genetic, Uterine Neoplasms, Gene Deletion, In Situ Hybridization, Fluorescence, Sequence Analysis, DNA, Germ-Line Mutation, Leiomyoma, Epithelioid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.